PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Protalix BioTherapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$2.56−0.06 (-2.29%)

Close on Oct 19, 2026

Market cap: $211.35M
P/E (TTM): 11.1
Dividend yield: –

Protalix BioTherapeutics, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31
Cash & Equivalents	15	20	24	17	39	18	18	38	51	63	76	55	86	52	27	36	81	43
Cash & Short-Term Investments	15	20	24	17	39	18	18	38	51	63	76	55	86	52	27	36	81	43
Receivables	8.84	2.91	5.27	4.59	3.44	2.00	4.70	4.73	1.72	0.69	0	1.88	2.09	1.41	1.37	7.01	–	–
Inventory	26	21	19	17	18	13	8.16	8.57	7.83	5.25	5.77	3.45	7.96	4.04	0.28	1.19	–	–
Prepaid Expenses & Other	0.39	0.50	0.44	0.77	0.91	0.84	0.31	0.45	0.43	0.42	0.41	0.37	0.29	0.25	0.24	–	–	–
Other Current Assets	1.13	1.10	1.06	1.31	1.29	2.10	1.83	1.88	1.93	2.65	1.67	2.20	1.46	–	–	–	–	–
Total Current Assets	67	60	70	45	62	56	32	53	63	72	86	66	98	61	32	46	–	–
Property, Plant & Equipment	4.88	4.59	4.97	4.55	4.96	4.85	5.27	6.39	7.68	8.70	9.74	11	14	16	18	17	–	–
Gross Property, Plant & Equipment	42	40	40	38	38	37	36	36	35	34	34	33	32	31	29	–	–	–
Accumulated Depreciation	-37	-36	-35	-34	-33	-32	-31	-29	-27	-26	-24	-21	-18	-15	-11	–	–	–
Operating Lease Right-of-Use Assets	7.70	5.43	5.91	5.09	4.96	5.57	5.68	0	–	–	–	–	–	–	–	–	–	–
Deferred Tax Assets	2.52	2.86	3.09	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Long-Term Assets	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.94	–	–
Total Assets	82	73	84	56	74	68	45	61	72	82	97	78	113	79	52	65	–	–
Accounts Payable	–	–	20	12	16	14	12	10	9.31	7.50	5.53	6.80	–	–	–	–	–	–
Accrued Expenses	9.79	9.57	9.01	7.48	12	9.59	7.36	6.37	4.80	3.58	1.57	3.11	1.79	2.03	2.33	–	–	–
Current Portion of Leases	1.38	1.50	1.41	1.12	1.21	1.42	1.14	0	–	–	–	–	–	–	–	–	–	–
Current Income Taxes Payable	2.95	3.48	2.88	0.53	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Deferred Revenue (Current)	–	–	0	13	8.55	5.39	16	9.87	–	0.84	0.50	0.89	9.37	9.44	6.12	4.56	–	–
Total Current Liabilities	27	26	46	32	33	86	40	25	23	66	11	64	27	26	19	19	–	–
Long-Term Debt	–	–	–	–	–	–	–	–	–	–	–	0.91	2.37	5.43	6.57	–	–	–
Long-Term Leases	6.94	4.03	4.62	4.17	4.38	4.47	4.53	0	–	–	–	–	–	–	–	–	–	–
Operating Lease Liabilities	8.32	5.53	6.03	5.29	5.58	5.89	5.70	5.70	–	–	–	–	–	–	–	–	–	–
Other Long-Term Liabilities	–	–	–	–	–	0.05	0.51	5.29	5.05	4.30	–	–	–	–	6.57	–	–	–
Total Liabilities	34	30	51	66	80	95	116	114	102	92	86	134	140	82	78	76	–	–
Total Debt	–	–	–	–	–	–	–	–	–	–	–	0.91	2.37	5.43	6.57	–	–	–
Common Stock	0.08	0.08	0.07	0.05	0.05	0.04	0.02	0.02	0.14	0.12	0.10	0.09	0.09	0.09	0.09	0.08	–	–
Additional Paid-In Capital	433	422	415	379	369	320	270	270	266	203	194	186	184	180	146	124	–	–
Retained Earnings	-385	-378	-382	-390	-375	-347	-341	-323	-296	-213	-183	-241	-211	-184	-172	-135	–	–
Shareholders' Equity	48	43	34	-11	-6.04	-27	-70	-53	-29	-9.96	11	-56	-27	-3.36	-26	-11	16	44
Total Equity	48	43	34	-11	-6.04	-27	-70	-53	-29	-9.96	11	-56	-27	-3.36	-26	-11	16	44
Total Liabilities & Equity	82	73	84	56	74	68	45	61	72	82	97	78	113	79	52	65	–	–
Shares Outstanding(shares)	80	76	73	54	46	35	15	15	14	12	9.98	9.36	9.36	9.35	8.56	8.12	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 69.2%
Operating margin: 28.9%
Net margin: 23.5%
Return on equity, FY2025: -14.4%

Financial strength

Current ratio: 2.94
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 87.3%

Valuation

P/E ratio: 11.1
Price to sales: 2.62
Price to book: 2.96
Dividend yield: –